Caesars Entertainment misses Q2 earnings expectations, shares edge lower
Amicus Therapeutics (NASDAQ:FOLD) stock recently reached a 52-week low, touching $5.55, with InvestingPro data showing the stock is currently trading at $5.59, slightly above its 52-week low. Despite the current price weakness, the company maintains impressive gross profit margins of 90.6% and strong liquidity with a current ratio of 3.34. This decline marks a significant downturn for the company, which has seen its stock price fall considerably over the past year. While the 1-year return shows a 42.15% decrease, the company has maintained solid revenue growth of 28.25%. According to InvestingPro analysis, the stock appears undervalued at current levels, with analyst price targets suggesting significant upside potential. Investors and analysts will be closely monitoring Amicus Therapeutics to assess any potential recovery or further declines in the near future. For deeper insights into Amicus Therapeutics’ valuation and growth prospects, access the comprehensive Pro Research Report available exclusively on InvestingPro, along with 10+ additional ProTips and detailed financial metrics.
In other recent news, Amicus Therapeutics reported its first-quarter 2025 earnings, which exceeded analyst expectations with an adjusted earnings per share of $0.03, compared to the forecasted -$0.02. However, the company’s revenue of $125.25 million fell short of Wall Street’s estimate of $136.65 million. Despite this, total revenue grew by 15% year-over-year, driven by a 6% increase in Galafold sales to $104.2 million and a 92% rise in Pombiliti + Opfolda sales to $21.0 million. Amicus Therapeutics adjusted its 2025 revenue growth guidance to 15-22% at constant exchange rates, down from the previous 17-24%. The company also announced licensing U.S. commercial rights to Dimerix’s DMX-200, a Phase 3 treatment for a rare kidney disease. In regulatory news, Japan’s Ministry of Health, Labour and Welfare approved Amicus Therapeutics’ Pombiliti + Opfolda for treating late-onset Pompe disease. The approval was based on data from the Phase 3 PROPEL study and adds Japan to the list of countries where the therapy is available.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.